VF
ADCT icon

Virtu Financial’s ADC Therapeutics ADCT Stock Holding History

Virtu Financial’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$30K Buy
28,174
+16,076
+133% +$46.9K ﹤0.01% 1297
2026
Q1 		$45K Buy
+12,098
New +$47.7K ﹤0.01% 1304
2025
Q3 		– Sell
-59,548
Closed -$160K – 1415
2025
Q2 		$160K Buy
+59,548
New +$125K 0.01% 962
2023
Q3 		– Sell
-18,835
Closed -$40K – 1223
2023
Q2 		$40K Buy
+18,835
New +$42.3K ﹤0.01% 1169

Other funds holding ADCT

NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Virtu Financial's ADCT Position: Q2 2026 in Review

Virtu Financial increased its ADC Therapeutics (ADCT) stake by 133% in Q2 2026, buying an estimated $46.9K and bringing the position to 28,174 shares worth $30K. The position accounts for ﹤0.01% of the portfolio, ranked #1297.

Virtu Financial first reported a position in ADCT in Q2 2023 and has held it in 4 quarters since. The position peaked at $160K in Q2 2025. 113 funds tracked by Wall St. Rank hold ADCT as of Q2 2026.

  • Virtu Financial held 28,174 shares of ADC Therapeutics worth $30K as of Q2 2026.
  • Virtu Financial bought 16,076 ADC Therapeutics shares in Q2 2026, an estimated $46.9K.
  • ADC Therapeutics made up ﹤0.01% of Virtu Financial's portfolio in Q2 2026, its #1297 holding.
  • Virtu Financial first reported a position in ADC Therapeutics in Q2 2023 and has held it in 4 quarters since.
  • Virtu Financial's ADC Therapeutics position peaked at $160K in Q2 2025.
  • 113 funds tracked by Wall St. Rank held ADC Therapeutics as of Q2 2026.

Based on Virtu Financial's 13F filing for Q2 2026, filed 13 Aug 2026.